News | November 21, 2023
AstraZeneca launches health-tech business ‘Evinova’
Evinova will operate as a separate health-tech business within AstraZeneca
Evinova will operate as a separate health-tech business within AstraZeneca
The product will be manufactured at Lupin’s Nagpur facility in India
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
The composition of ORAAL is protected by a granted patent in India until November 2033
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Subscribe To Our Newsletter & Stay Updated
